Literature DB >> 9605392

Analysis of creatine kinase activity in 504 patients with proximal spinal muscular atrophy types I-III from the point of view of progression and severity.

S Rudnik-Schöneborn1, S Lützenrath, J Borkowska, A Karwanska, I Hausmanowa-Petrusewicz, K Zerres.   

Abstract

Mild to moderately elevated creatine kinase (CK) activity is a frequent biochemical finding in proximal spinal muscular atrophy (SMA). In a collaborative study on all types of childhood and juvenile onset SMA, we analysed the CK activity of 504 SMA patients (138 type I, 127 type II, 144 type IIIa, and 95 type IIIb patients). Under the assumption of a lognormal distribution of CK activity as the most appropriate statistical model, CK levels were transformed into logarithms and compared by standard deviation scores = CK-SDS (log). CK activity was statistically different between early and later onset SMA: in SMA I and II, about one-third of patients showed CK-SDS (log) >2 SD, the analysis of the means did not show significant differences. In SMA III, CK-SDS (log) was significantly higher (p < 0.01) than in the two other groups, which was most pronounced in SMA IIIb. More than 90% of SMA IIIb patients showed CK-SDS (log) values >2 vs. 57% in SMA IIIa. As similar values were obtained for a subgroup of 100 patients in whom the diagnosis of autosomal recessive SMA was confirmed by a deletion of the telomeric copy of the survival motor neuron gene, our results can be considered representative for SMA I-III. There was no correlation between CK level and disease duration. The fact that patients were ambulatory or chair-bound had no influence on CK activity in type III SMA. There was no sex influence in SMA I, II and IIIa. The observed higher male values in the group SMA IIIb are most likely the result of a lack of female patients with onset after puberty.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605392     DOI: 10.1159/000007926

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  5 in total

1.  Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.

Authors:  Claudia D Wurster; Petra Steinacker; René Günther; Jan C Koch; Paul Lingor; Zeljko Uzelac; Simon Witzel; Kurt Wollinsky; Benedikt Winter; Alma Osmanovic; Olivia Schreiber-Katz; Rami Al Shweiki; Albert C Ludolph; Susanne Petri; Andreas Hermann; Markus Otto
Journal:  J Neurol       Date:  2019-09-24       Impact factor: 4.849

2.  Biomarkers of therapeutic efficacy in adolescents and adults with 5q spinal muscular atrophy: a systematic review.

Authors:  Maria Gavriilaki; Vasileios Papaliagkas; Alexandra Stamperna; Maria Moschou; Konstantinos Notas; Sotirios Papagiannopoulos; Marianthi Arnaoutoglou; Vasilios K Kimiskidis
Journal:  Acta Neurol Belg       Date:  2022-07-21       Impact factor: 2.471

3.  Observational study of spinal muscular atrophy type I and implications for clinical trials.

Authors:  Richard S Finkel; Michael P McDermott; Petra Kaufmann; Basil T Darras; Wendy K Chung; Douglas M Sproule; Peter B Kang; A Reghan Foley; Michelle L Yang; William B Martens; Maryam Oskoui; Allan M Glanzman; Jean Flickinger; Jacqueline Montes; Sally Dunaway; Jessica O'Hagen; Janet Quigley; Susan Riley; Maryjane Benton; Patricia A Ryan; Megan Montgomery; Jonathan Marra; Clifton Gooch; Darryl C De Vivo
Journal:  Neurology       Date:  2014-07-30       Impact factor: 9.910

4.  Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.

Authors:  Nadine Beckmann; Katrin Anne Becker; Stephanie Kadow; Fabian Schumacher; Melanie Kramer; Claudine Kühn; Walter J Schulz-Schaeffer; Michael J Edwards; Burkhard Kleuser; Erich Gulbins; Alexander Carpinteiro
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

5.  Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment.

Authors:  Maren Freigang; Claudia D Wurster; Tim Hagenacker; Benjamin Stolte; Markus Weiler; Christoph Kamm; Olivia Schreiber-Katz; Alma Osmanovic; Susanne Petri; Alexander Kowski; Thomas Meyer; Jan C Koch; Isabell Cordts; Marcus Deschauer; Paul Lingor; Elisa Aust; Daniel Petzold; Albert C Ludolph; Björn Falkenburger; Andreas Hermann; René Günther
Journal:  Ann Clin Transl Neurol       Date:  2021-03-31       Impact factor: 4.511

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.